Ceapro Inc. Reports 2023 Second Quarter and Six-Month Financial Results and Provides Corporate Update
29 août 2023 09h05 HE
|
Ceapro Inc.
- $5.5 million first six-month 2023 sales vs. $11.7 million for the same period in 2022; sales lagging by one quarter due to stocking campaign by one major customer in 2022 and further Marketplace...
Ceapro Extends Exclusive International Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise
25 août 2023 09h05 HE
|
Ceapro Inc.
– Exclusive agreement extended from 3 to 5 years until December 31, 2026 – Supply and distribution agreement provides Symrise with exclusivity for several major key international customers in the...
Ceapro Announces Next Phase of Research Collaboration with the Angiogenesis Foundation
18 juil. 2023 09h05 HE
|
Ceapro Inc.
– New studies to focus on speed of healing and molecular profiling of tissue regeneration induced by oat-derived bioactive products – EDMONTON, Alberta, July 18, 2023 (GLOBE NEWSWIRE) -- Ceapro...
Ceapro to Participate in the Virtual Investor Summer Spotlight Series
05 juil. 2023 08h45 HE
|
Ceapro Inc.
EDMONTON, Alberta, July 05, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Announces Results of 2023 Shareholders’ Meeting
07 juin 2023 09h05 HE
|
Ceapro Inc.
EDMONTON, Alberta, June 07, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Inc. Reports Financial Results for First Quarter 2023 and Provides Corporate Update
25 mai 2023 09h00 HE
|
Ceapro Inc.
– Q1 2023 sales of $3,500,000 vs $6,172,000 in Q1 2022 – Ended the quarter with $12.6 million in cash allowing funding for planned pipeline development EDMONTON, Alberta, May 25, 2023 (GLOBE...
Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases
23 mai 2023 08h45 HE
|
Ceapro Inc.
– Results from the completed Collaborative Health Research Projects (CHRP) study with McMaster University presented at the American Thoracic Society (ATS) International Conference – – Data...
Ceapro Announces Positive Findings Demonstrating Oat Derived Beta Glucan and Avenanthramides Promote Wound Healing and Tissue Regeneration
03 mai 2023 08h05 HE
|
Ceapro Inc.
– Data presented at 2023 Annual Meeting of the Wound Healing Society showed statistically significant results characterizing the in vivo bioactivity of Ceapro’s oat-derived bioactive products on wound...
Ceapro Inc. Appoints Michel Regnier as Senior Vice President, Technical Operations
27 avr. 2023 08h05 HE
|
Ceapro Inc.
EDMONTON, Alberta, April 27, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO, OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Inc. Reports Record 2022 Financial Results and Operational Highlights
12 avr. 2023 09h00 HE
|
Ceapro Inc.
– 2022 marks Ceapro’s best performance in Company history with record sales of $18,800,000 compared to $17,200,000 for 2021, representing a 10% increase year over year – Net profit after tax of...